Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
about
CFTR Modulators: Shedding Light on Precision Medicine for Cystic FibrosisImproved fluorescence assays to measure the defects associated with F508del-CFTR allow identification of new active compounds.Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.Strategies in early clinical development for the treatment of basic defects of cystic fibrosis.Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation.Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?Effects of Pseudomonas aeruginosa on CFTR chloride secretion and the host immune response.Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO.Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients.Mutation-specific downregulation of CFTR2 variants by gating potentiators.Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa.Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences.The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites.Molecular basis of cystic fibrosis: from bench to bedsideEmerging microRNA Therapeutic Approaches for Cystic FibrosisSweat rate analysis of ivacaftor potentiation of CFTR in non-CF adultsProlonged co-treatment with HGF sustains epithelial integrity and improves pharmacological rescue of Phe508del-CFTR
P2860
Q28073996-7F661190-FC19-4010-B24E-71B5FF2B478CQ36251047-47A5C4AC-58CD-469C-A088-686F7BD2E927Q38721354-D8D72A6C-1D30-4769-BCE3-6C7D49F188F5Q38733938-5DB4BE20-8FFA-4791-824C-08EF672C19EDQ38835405-B57D1510-3595-4C9C-9314-FCE096EE55C3Q38890926-46F2CA48-4E3B-432B-8CB5-27E114E21755Q38996435-F77606FD-F966-4C1F-93DB-80ACA7693EF9Q39103385-DC858C75-BCC9-4072-A14D-3A9EA0A988AEQ39603833-F5D8ACC6-64B5-4169-A735-D4BC1801FB28Q45055159-74279DDE-4195-4954-AF66-04FD4A6F2239Q47384854-D8F6FD89-EA63-43C0-A535-5831D5CABF84Q47741272-10B6230B-C1A8-4D27-8A0A-9B0A79619C7CQ47824569-6A68E3F7-BF5A-4A7F-BF0E-BB79481851DBQ48543107-5E3B75B9-C67D-491F-82FA-ED9ED29ADC5FQ50605358-57115B13-D209-4F7C-9A77-FD537028096FQ52645796-8414DBA3-9F78-461E-B6D3-A06DD6CA967DQ57300566-D3B12F2F-727A-42EF-98A5-2D3894383C47Q57817593-003963DB-4736-4831-AC79-5305425CC0A4Q58618239-11CF432B-9BCD-4EA4-9F73-FB0E75B89CBAQ58695729-AE3FADC1-C361-491E-A5DD-41C0CAAA745E
P2860
Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Low free drug concentration pr ...... otentiator VX-770 (ivacaftor).
@en
type
label
Low free drug concentration pr ...... otentiator VX-770 (ivacaftor).
@en
prefLabel
Low free drug concentration pr ...... otentiator VX-770 (ivacaftor).
@en
P2093
P2860
P356
P1476
Low free drug concentration pr ...... potentiator VX-770 (ivacaftor)
@en
P2093
Arnaud Billet
Elizabeth Matthes
Graeme W Carlile
John W Hanrahan
Julie Goepp
Kurt Dejgaard
Renaud Robert
Yishan Luo
P2860
P304
P356
10.1111/BPH.13365
P407
P577
2016-01-13T00:00:00Z